Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study by �젙�쁽泥�
Vol:.(1234567890)
Gastric Cancer (2019) 22:828–837
https://doi.org/10.1007/s10120-018-00909-5
1 3
ORIGINAL ARTICLE
Pembrolizumab alone or in combination with chemotherapy as first-
line therapy for patients with advanced gastric or gastroesophageal 
junction adenocarcinoma: results from the phase II nonrandomized 
KEYNOTE-059 study
Yung‑Jue Bang1 · Yoon‑Koo Kang2 · Daniel V. Catenacci3 · Kei Muro4 · Charles S. Fuchs5 · Ravit Geva6 · Hiroki Hara7 · 
Talia Golan8 · Marcelo Garrido9 · Shadia I. Jalal10 · Christophe Borg11 · Toshihiko Doi12 · Harry H. Yoon13 · 
Mary J. Savage14 · Jiangdian Wang14 · Rita P. Dalal14 · Sukrut Shah14 · Zev A. Wainberg15 · Hyun Cheol Chung16
Received: 5 September 2018 / Accepted: 1 December 2018 / Published online: 25 March 2019 
© The Author(s) 2019
Abstract
Background The multicohort, phase II, nonrandomized KEYNOTE-059 study evaluated pembrolizumab ± chemotherapy in 
advanced gastric/gastroesophageal junction cancer. Results from cohorts 2 and 3, evaluating first-line therapy, are presented.
Methods Patients ≥ 18 years old had previously untreated recurrent or metastatic gastric/gastroesophageal junction adeno-
carcinoma. Cohort 3 (monotherapy) had programmed death receptor 1 combined positive score ≥ 1. Cohort 2 (combina-
tion therapy) received pembrolizumab 200 mg on day 1, cisplatin 80 mg/m2 on day 1 (up to 6 cycles), and 5-fluorouracil 
800 mg/m2 on days 1–5 of each 3-week cycle (or capecitabine 1000 mg/m2 twice daily in Japan). Primary end points were 
safety (combination therapy) and objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 by 
central review, and safety (monotherapy).
Results In the combination therapy and monotherapy cohorts, 25 and 31 patients were enrolled; median follow-up was 
13.8 months (range 1.8–24.1) and 17.5 months (range 1.7–20.7), respectively. In the combination therapy cohort, grade 3/4 
treatment-related adverse events occurred in 19 patients (76.0%); none were fatal. In the monotherapy cohort, grade 3–5 
treatment-related adverse events occurred in seven patients (22.6%); one death was attributed to a treatment-related adverse 
event (pneumonitis). The objective response rate was 60.0% [95% confidence interval (CI), 38.7–78.9] (combination therapy) 
and 25.8% (95% CI 11.9–44.6) (monotherapy).
Conclusions Pembrolizumab demonstrated antitumor activity and was well tolerated as monotherapy and in combination 
with chemotherapy in patients with previously untreated advanced gastric/gastroesophageal junction adenocarcinoma.
Clinical Trial ClinicalTrials.gov NCT02335411
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Introduction
Gastric cancer is the fifth most common malignancy world-
wide. In 2012, it led to 723,000 deaths [1]. Most cases are 
advanced at diagnosis, and prognosis is poor [2, 3]. Chemo-
therapy containing fluoropyrimidine plus a platinum agent is 
standard first-line treatment for advanced gastric or gastroe-
sophageal junction (G/GEJ) adenocarcinoma not expressing 
human epidermal growth factor receptor 2 (HER2) [4–6]. 
In previously untreated gastric cancer, this regimen dem-
onstrated objective response rates (ORRs) of 25–48% and 
median overall survival (OS) of 8–11.2 months [7–12].
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Tumor cells frequently use the programmed death recep-
tor 1 (PD-1) pathway to evade immune surveillance [13, 14]. 
Binding of PD-1 to its ligands, PD-L1 and PD-L2, inhibits 
effector T-cell function, resulting in suppression of antitu-
mor immune response [13, 14]. PD-L1 is frequently upregu-
lated in gastric cancer [15–19]. Pembrolizumab is a selec-
tive, humanized, immunoglobulin G4κ monoclonal antibody 
that blocks interactions between PD-1 and its ligands [20]. 
The phase II KEYNOTE-059 clinical trial, a multicohort 
study designed to evaluate pembrolizumab alone or in com-
bination with chemotherapy in patients with recurrent or 
metastatic G/GEJ adenocarcinoma, included a cohort of 
patients whose disease had progressed while they previously 
received at least two systemic therapies for advanced disease 
(cohort 1; pembrolizumab monotherapy) and two cohorts of 
patients who had not previously received systemic therapy 
for advanced disease. Data from cohort 1 have already been 
published and demonstrate durable responses with pembroli-
zumab monotherapy, with higher ORR and longer response 
durations in patients with PD-L1-positive tumors [com-
bined positive score (CPS) ≥ 1] than with PD-L1-negative 
tumors [21]. Based on these results, the US Food and Drug 
Administration approved pembrolizumab for the treatment 
of patients with recurrent or metastatic G/GEJ adenocarci-
noma whose tumors express PD-L1 and whose disease has 
progressed on or after ≥ 2 prior lines of therapy [20]. In the 
phase III, KEYNOTE-061 study, pembrolizumab did not 
significantly improve OS, versus paclitaxel, as second-line 
therapy in patients with advanced G/GEJ cancer and PD-L1 
CPS ≥ 1 [22].
Chemotherapeutic agents such as cisplatin and 5-fluoro-
uracil enhance immunogenicity of cancer cells and increase 
susceptibility to immune-mediated cytotoxicity [23–25]. 
Combining pembrolizumab with chemotherapy has dem-
onstrated efficacy and manageable safety in other cancers 
[26, 27]. Cohorts 2 and 3 of the KEYNOTE-059 study were 
designed to further explore pembrolizumab in combination 
therapy and as monotherapy in the PD-L1-positive popula-
tion. Herein, we present results from cohorts 2 and 3 of the 
KEYNOTE-059 study, which evaluated first-line therapy 
with pembrolizumab plus chemotherapy (cohort 2) or alone 
(cohort 3) in advanced G/GEJ cancer.
Materials and methods
KEYNOTE-059 is a multicenter, open-label, nonrand-
omized, 3-cohort, phase II study. Results for cohorts 2 and 3 
are presented; results for cohort 1 were published separately 
[21]. The study was conducted in accordance with Good 
Clinical Practice guidelines and the Declaration of Helsinki. 
The protocol was approved by institutional review boards 
and independent ethics committees for each institution. All 
patients provided written, informed consent. This trial was 
registered with ClinicalTrials.gov, number NCT02335411.
Patients
Eligibility criteria for both cohorts were age ≥ 18 years, 
histologically or cytologically confirmed recurrent or meta-
static G/GEJ adenocarcinoma, no prior systemic therapy for 
advanced disease, measurable disease per Response Evalua-
tion Criteria in Solid Tumors version 1.1 (RECIST v1.1) by 
central review, HER2/neu-negative status, Eastern Coopera-
tive Oncology Group performance status 0/1, life expectancy 
≥ 3 months, and adequate organ function.
For cohort 2, patients had to provide new or archival 
tumor tissue for PD-L1 analysis. For cohort 3, patients had 
to have PD-L1-positive tumors as per the PD-L1 IHC 22C3 
pharmDx assay (Agilent Technologies, Carpinteria, CA, 
USA). PD-L1 positivity was defined as CPS ≥ 1, where CPS 
is the number of PD-L1-positive cells (tumor cells, lymph-
ocytes, and macrophages) divided by the total number of 
tumor cells multiplied by 100 [21]. Exclusion criteria are 
presented in Online Resource Table S1. We assessed DNA 
mismatch repair across 5 mononucleotide repeat markers 
(NR21, NR24, BAT25, BAT26, MONO27) using DNA 
extracted from formalin-fixed, paraffin-embedded tumor 
samples and blood (normal control) using the MSI Analysis 
System, version 1.2 (Promega). In microsatellite instability-
high tumors, 2 or more markers were changed, compared 
with normal controls.
Study treatment
In cohort 2, patients received pembrolizumab 200 mg by 
intravenous infusion over 30 min on day 1, cisplatin 80 mg/
m2 on day 1 (for up to 6 cycles), and 5-fluorouracil 800 mg/
m2 by continuous infusion on days 1–5 of each 21-day cycle. 
In Japan only, patients received capecitabine 1000 mg/m2 
twice daily orally on days 1–14 of each 21-day cycle instead 
of 5-fluorouracil. Up to two dose reductions were allowed 
per chemotherapy agent (Online Resource Table S2). In 
cohort 3, patients received pembrolizumab monotherapy 
200 mg by intravenous infusion over 30 min on day 1 of 
each 21-day cycle.
Pembrolizumab dose reduction was not permitted. Treat-
ment was continued for up to 35 cycles (~ 2 years) or until 
confirmed disease progression, unacceptable toxicity, 
complete response, or patient or investigator decision to 
withdraw. Clinically stable patients with radiographic pro-
gressive disease (PD) could continue treatment at the inves-
tigator’s discretion until confirmed PD. Patients in cohort 2 
who discontinued chemotherapy could continue pembroli-
zumab if they had not met criteria for discontinuation.
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Outcomes and assessments
For cohort 2, the primary end points were safety and toler-
ability. Secondary end points included ORR (percentage 
of patients who experienced complete or partial response) 
per RECIST v1.1 by central imaging review and evalua-
tion of the relationship between PD-L1 expression and 
efficacy. For cohort 3, primary end points were ORR and 
safety and tolerability. Secondary end points included dis-
ease control rate (DCR; percentage of patients who expe-
rienced complete or partial response or stable disease for 
≥ 6 months), duration of response, progression-free sur-
vival (PFS; time from study treatment initiation to first 
documented instance of PD or death) per RECIST v1.1 
by central imaging review, and OS (time from initiation 
of study treatment to death from any cause).
Tumors were assessed by computed tomography 
or magnetic resonance imaging at 9 weeks after study 
treatment initiation, every 6 weeks for year 1, and every 
9 weeks thereafter (or more often if clinically indicated). 
Response was confirmed by repeat radiographic assess-
ment ≥ 4 weeks after first documentation. Patients were 
followed up every 12 weeks for survival status until death, 
withdrawal of consent, or study end.
Patients were monitored for adverse events (AEs) until 
30 days after the last dose of treatment (90 days for seri-
ous AEs and events of clinical interest). AEs were graded 
using National Cancer Institute Common Terminology 
Criteria for Adverse Events, version 4.0; investigators 
determined treatment attribution.
Statistical analysis
For cohort 2, the sample size was based on clinical experi-
ence. A sample size of ~ 18 patients was planned to pro-
vide the reasonable two-sided 95% confidence interval (CI) 
of AE incidence (Online Resource Table S3). For cohort 
3, a sample size of ~ 25 patients with PD-L1 CPS ≥ 1 was 
estimated using Bayesian sample size methods assuming 
a uniform prior for the response rate and a true ORR of 
< 40% (ORR based on standard of care). Safety and effi-
cacy were analyzed in all patients who received ≥ 1 dose 
of study treatment. Safety was analyzed using descriptive 
statistics. Analyses were conducted using SAS statistical 
software version 9.3 (SAS Institute, Inc). ORR and DCR 
with 95% CI were calculated using the exact method based 
on binomial distribution (Clopper–Pearson method [28]). 
Patients with missing data were considered nonrespond-
ers. Time-to-event end points were estimated using the 
Kaplan–Meier method, with censoring at the last date of 
assessment for patients with missing data.
Results
The study was conducted at 57 sites in 17 countries. 
For cohort 2, 25 patients were enrolled at 10 sites in the 
Republic of Korea (South Korea), Japan, Israel, the United 
States, and France between March 2, 2015, and December 
14, 2015. For cohort 3, 31 patients were enrolled at 18 
sites in Canada, Chile, Israel, Japan, South Korea, and 
the United States between July 23, 2015, and December 
2, 2015. Patient characteristics are presented in Table 1.
At data cutoff (April 21, 2017), median follow-up was 
13.8 months (range 1.8–24.1) in cohort 2 and 17.5 months 
(range 1.7–20.7) in cohort 3. In cohort 2, 22 patients 
(88.0%) had discontinued study treatment and three 
(12.0%) remained on treatment. In cohort 3, 24 patients 
(77.4%) had discontinued study treatment, whereas seven 
patients (22.6%) remained on treatment. In both cohorts, 
Table 1  Patient characteristics
Unless otherwise indicated, all data are n (%)
CPS combined positive score, ECOG Eastern Cooperative Oncol-
ogy Group, PD-L1 programmed death ligand 1, WHO World Health 
Organization
Characteristic Cohort 2
N = 25
Cohort 3
N = 31
Male 16 (64.0) 19 (61.3)
Age, median (range) (years) 64 (21–82) 62 (32–75)
Race
 Asian 17 (68.0) 15 (48.4)
 White 8 (32.0) 16 (51.6)
Region
 United States 3 (12.0) 12 (38.7)
 East Asia 16 (64.0) 13 (41.9)
 Rest of world 6 (24.0) 6 (19.4)
ECOG performance status
 0 15 (60.0) 14 (45.2)
 1 10 (40.0) 17 (54.8)
Metastatic stage
 M0 1 (4.0) 5 (16.1)
 M1 24 (96.0) 26 (83.9)
 Prior surgery for gastric cancer 5 (20.0) 12 (38.7)
Histology, WHO classification
 Tubular adenocarcinoma 22 (88.0) 25 (80.6)
 Signet ring cell carcinoma 2 (8.0) 3 (9.7)
 Mixed carcinoma 1 (4.0) 2 (6.5)
 Other poorly cohesive carcinoma 0 1 (3.2)
PD-L1 expression
 CPS ≥ 1 16 (64.0) 31 (100.0)
 CPS < 1 8 (32.0) 0
 Unknown 1 (4.0) 0
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the most common reason for treatment discontinuation was 
PD (Online Resource Figure S1, CONSORT).
Treatment exposure and safety
Cohort 2
Median duration of pembrolizumab exposure was 
7.1 months (range 0.8–23.8), and median number of admin-
istrations was 10 (range 2–35). All patients experienced 
treatment-related AEs (TRAEs) (Table 2). Grade 3 TRAEs 
occurred in 15 patients (60.0%). One TRAE was grade 4 
(decreased neutrophil count, 16.0%). No TRAEs were fatal. 
AEs and serious AEs related to chemotherapy and pem-
brolizumab are presented in Online Resource Tables S4 and 
S5. TRAEs leading to treatment interruption are described 
in Online Resource Table S6. Three patients (12.0%) dis-
continued treatment because of chemotherapy-related AEs: 
grade 3 stomatitis, grade 2 hypoacusis, and grade 1 increased 
creatinine level. No patient discontinued treatment because 
of pembrolizumab-related AEs. Immune-mediated AEs 
(regardless of attribution) occurred in 12 patients (48.0%) 
and were grade 3 in four patients (16.0%) (Online Resource 
Table S7). No grade 4/5 immune-mediated AEs occurred. 
Five of 12 patients who experienced an immune-mediated 
AE (41.7%) received systemic corticosteroids.
Cohort 3
Median duration of exposure to pembrolizumab was 
2.8 months (range 0.7–20.3), and median number of admin-
istrations was five (range 2–30). Overall, TRAEs occurred in 
24 patients (77.4%) (Table 3). Grade 3–5 TRAEs occurred 
in seven patients (22.6%). One patient died because of pneu-
monitis 74 days after the last pembrolizumab dose. Serious 
TRAEs occurred in six patients (19.4%). TRAEs resulted 
in treatment interruption in eight patients (25.8%) (Online 
Resource Table S8). No patient discontinued because of 
a TRAE. Immune-mediated AEs occurred in 10 patients 
(32.3%) and were grade 3–5 in three patients (9.7%) 
(Online Resource Table S9). Four of ten patients who expe-
rienced an immune-mediated AE (40.0%) received systemic 
corticosteroids.
Antitumor activity
Cohort 2
Confirmed ORR was 60.0% (95% CI 39.0–79.0), with com-
plete response in one patient (4.0%) (Table 4). Median time 
to response was 2.1 months (range 1.9–3.7) and median 
response duration was 4.6 months (range 2.6–20.3+). At 
data cutoff, response was ongoing in two of 15 responders 
(13.3%), with response durations of 20.0  months and 
20.3 months, respectively. No patient in cohort 2 had micro-
satellite instability-high tumors.
Reductions in target lesion size from baseline were 
observed in all 24 patients (100%) who had measurable dis-
ease at baseline and ≥ 1 evaluable postbaseline assessment 
(Fig. 1a). Responders generally experienced reduction in 
Table 2  Treatment-related AEs of any grade occurring in ≥ 10% of 
patients and grade 3 treatment-related AEs occurring in ≥ 1 patients 
in cohort 2
AE adverse event, WBC white blood cell
a Attribution of AEs to study treatment was determined by the inves-
tigator
b Stomatitis refers to inflammation of the mouth and lips
c Mucosal inflammation refers to inflammation of the mucous mem-
branes
Treatment-related  AEsa n (%) Cohort 2
N = 25
Any grade Grade 3
Any 25 (100.0) 15 (60.0)
Hematologic
 Decreased neutrophil count 21 (84.0) 12 (48.0)
 Anemia 5 (20.0) 2 (8.0)
 Decreased platelet count 8 (32.0) 2 (8.0)
 Decreased WBC count 4 (16.0) 1 (4.0)
 Febrile neutropenia 1 (4.0) 1 (4.0)
Nonhematologic
 Nausea 13 (52.0) 1 (4.0)
 Stomatitisb 13 (52.0) 5 (20.0)
 Decreased appetite 11 (44.0) 2 (8.0)
 Fatigue 8 (32.0) 2 (8.0)
 Diarrhea 8 (32.0) 0
 Dysgeusia 7 (28.0) 0
 Constipation 6 (24.0) 0
 Vomiting 6 (24.0) 0
 Hiccups 5 (20.0) 0
 Malaise 5 (20.0) 0
 Palmar–plantar erythrodysesthesia 
syndrome
4 (16.0) 2 (8.0)
 Alopecia 4 (16.0) 0
 Peripheral sensory neuropathy 4 (16.0) 0
 Hyperthyroidism 4 (16.0) 0
 Maculopapular rash or rash 4 (16.0) 2 (8.0)
 Pyrexia 3 (12.0) 1 (4.0)
 Decreased weight 3 (12.0) 1 (4.0)
 Increased blood creatinine level 3 (12.0) 0
 Mucosal  inflammationc 3 (12.0) 0
 Peripheral neuropathy 3 (12.0) 0
 Increased weight 3 (12.0) 0
 Hypophosphatemia 1 (4.0) 1 (4.0)
 Polymyalgia rheumatica 1 (4.0) 1 (4.0)
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tumor burden within a few months (Fig. 1b; Online Resource 
Figure S2).
In cohort 2, 16 patients had PD-L1 CPS ≥ 1 and 
eight had PD-L1 CPS < 1. Among the 16 patients with 
PD-L1 CPS ≥ 1, ORR was 68.8% (95% CI 41.3–89.0%; 
Online Resource Table S10), median time to response 
was 2.1 months (range 1.9–3.5), and median duration of 
response was 4.6 months (range 3.2–18.1+). Among the 
eight patients with PD-L1 CPS < 1, ORR was 37.5% (95% 
CI 8.5–75.5%), median time to response was 3.6 months 
(range 2.1–3.7), and median duration of response was 
5.4 months (range 2.8–10.1+).
Among 19 patients receiving pembrolizumab, cisplatin, 
and 5-fluorouracil, ORR was 57.9% (96% CI 33.5–79.7%). 
Among six Japanese patients receiving pembrolizumab, 
cisplatin, and capecitabine, ORR was 66.7% (95% CI 
22.3–95.7%) (Online Resource Table S11).
Cohort 3
Confirmed ORR was 25.8% (95% CI 11.9–44.6%), with 
complete response in two patients (6.5%) (Table  3). 
Median time to response was 2.1 months (range 1.5–6.2) 
and median response duration was 9.6  months (range 
2.1–17.8+) (Table 3). Response was ongoing at data cut-
off in three of eight responders (37.5%), with response 
durations of 17.4, 13.7, and 17.8 months. One patient in 
cohort 3 had microsatellite instability-high tumors and 
experienced a partial response.
Of 28 patients with measurable disease at baseline who 
had ≥ 1 evaluable postbaseline assessment, 24 (85.7%) 
experienced reduction in target lesion size from baseline 
(Fig. 1c). Decrease in tumor burden was generally main-
tained over several assessments (Fig. 1d; Online Resource 
Figure S2).
Table 3  Treatment-related AE of any grade occurring in ≥ 10% of 
patients and grade 3 treatment-related AEs occurring in ≥ 1 patient 
in cohort 3
AE adverse event
a Attribution of AEs to study treatment was determined by the inves-
tigator
Treatment-related  AEsa n (%) Cohort 3
N = 31
Any grade Grade 3
Any 24 (77.4) 6 (19.4)
Fatigue 8 (25.8) 0
Pruritus 7 (22.6) 0
Pneumonitis 4 (12.9) 0
Bile duct obstruction 1 (3.2) 1 (3.2)
Colitis 1 (3.2) 1 (3.2)
Dehydration 1 (3.2) 1 (3.2)
Diffuse uveal melanocytic proliferation 1 (3.2) 1 (3.2)
Hyponatremia 1 (3.2) 1 (3.2)
Neutropenia 1 (3.2) 1 (3.2)
Rash 1 (3.2) 1 (3.2)
Table 4  Antitumor  activitya assessed by central review per RECIST v1.1 and duration of response
The + indicates that there was no progressive disease at last disease assessment
CI confidence interval, RECIST Response Evaluation Criteria in Solid Tumors
a Confirmed by repeat radiographic assessment ≥ 4 weeks after first documentation of response
b Based on binomial exact CI method
c Complete response + partial response
d Complete response + partial response + stable disease maintained for ≥ 6 months
Category Cohort 2
N = 25
Cohort 3
N = 31
n % (95%  CIb) n % (95%  CIb)
Objective response  ratec 15 60.0 (38.7–78.9) 8 25.8 (11.9–44.6)
Disease control  rated 20 80.0 (59.3–93.2) 11 35.5 (19.2–54.6)
Best overall response
 Complete response 1 4.0 (0.1–20.4) 2 6.5 (0.8–21.4)
 Partial response 14 56.0 (34.9–75.6) 6 19.4 (7.5–37.5)
 Stable disease 8 32.0 (14.9–53.5) 9 29.0 (14.2–48.0)
 Progressive disease 1 4.0 (0.1–20.4) 12 38.7 (21.8–57.8)
 Nonevaluable/no assessment 1 4.0 (0.1–20.4) 2 6.5 (0.8–21.4)
Median (range) time to response (months) 2.1 (1.9–3.7) 2.1 (1.5–6.2)
Median (range) duration of response (months) 4.6 (2.6–20.3+) 9.6 (2.1–17.8+)
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Survival outcomes
Cohort 2
Median PFS was 6.6  months (95% CI 5.9–10.6), and 
estimated PFS rate at 6  months was 68.0% (Fig.  2a). 
Median OS was 13.8 months (95% CI 8.6—not estima-
ble), and estimated OS rates were 52% and 48% at 12 and 
18 months, respectively (Fig. 2b). In patients with PD-L1 
CPS ≥ 1 and < 1, median OS was 11.1 months (95% CI 
5.4–22.3) and 19.8 months (95% CI 1.8—not estimable), 
respectively.
Cohort 3
Median PFS was 3.3 months (95% CI 2.0–6.0 months), and 
estimated PFS rate at 6 months was 34.9% (Fig. 2c). Median 
OS was 20.7 months (95% CI 9.2–20.7), and estimated OS 
rates were 63% and 55% at 12 and 18 months, respectively 
(Fig. 2d).
C
ha
ng
e 
fr
om
 b
as
el
in
e 
(%
)
20
0
–20
–40
–60
–80
–10
PD-L1 expression unknown
PD-L1 negative
PD-L1 positive
Pa
tie
nt
s
Time since treatment initiation (months)
Complete response
Partial response
Progressive disease
Death
Ongoing response
C
ha
ng
e 
fr
om
 b
as
el
in
e 
(%
)
20% increase in tumor size
30% decrease in tumor size
100
80
60
40
20
0
–20
–40
–60
–80
–10
Pa
tie
nt
s
Time since treatment initiation (months)
Complete response
Partial response
Progressive disease
Ongoing response
a
b
c
d
24222010860 12 14 16 182 4
Fig. 1  Antitumor activity. a Best change from baseline in the sum 
of longest target lesion diameters per patient by PD-L1 expression 
in cohort 2 (n = 24)a. b Duration of exposure and best response in 
confirmed responders in cohort 2 (n = 15)b. c Maximum percentage 
change from baseline in the sum of longest diameter of target lesions 
per patient (n = 28)a. d Duration of exposure and best response in 
confirmed responders (n = 8)b. aPatients with measurable disease 
per RECIST v1.1 by central review at baseline who had ≥ 1 evalu-
able postbaseline assessment. bPatients with measurable disease per 
RECIST v1.1 by central review at baseline who had ≥ 1 postbaseline 
assessment and had confirmed response. Bar length indicates time to 
last dose of study drug. Time to first confirmed response is shown. 
PD-L1, programmed death ligand 1; RECIST v1.1, Response Evalua-
tion Criteria in Solid Tumors version 1.1
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Discussion
Cohort 1 of the KEYNOTE-059 study confirmed that 
pembrolizumab monotherapy provided durable responses 
with manageable safety in patients with advanced G/GEJ 
adenocarcinoma that had progressed following second-line 
treatment [21]. Although patient numbers in the current 
analyses were small, results from cohorts 2 and 3 of the 
KEYNOTE-059 study demonstrated manageable safety 
and antitumor activity for pembrolizumab as monotherapy 
and as combination therapy with cisplatin plus 5-fluoro-
uracil or capecitabine in previously untreated advanced 
G/GEJ adenocarcinoma. Although it is difficult to draw 
definitive conclusions regarding the clinical impact of 
pembrolizumab based solely on these data, the results, 
along with those from cohort 1 of the study [21], sup-
port the growing body of evidence for the potential use of 
pembrolizumab in patients with G/GEJ adenocarcinoma. 
Additional large-scale clinical trials are needed to confirm 
efficacy and safety in these patients.
In cohort 2, the incidence and severity of TRAEs 
with pembrolizumab plus cisplatin plus 5-fluorouracil 
or capecitabine were generally consistent with those of 
known toxic effects of cisplatin plus fluoropyrimidine [7, 
9, 10, 12]. The incidence of grades 3 and 4 chemotherapy-
related neutropenia (48% and 16%, respectively) in this 
cohort was somewhat higher than expected; previous stud-
ies of first-line chemotherapy in patients with advanced 
gastric cancer have reported grade ≥ 3 neutropenia occur-
ring at rates of 20–44% [29–31], although these data were 
collected from larger study populations that may not be 
directly comparable. It is notable that neutropenia levels 
were not elevated in either cohort 3 or cohort 1 [21], but, 
with a population of just 25 patients, it is difficult to draw 
definitive conclusions as to the cause of the slightly greater 
incidence in cohort 2. The incidence of pembrolizumab-
related stomatitis (12% overall; 8% grade 3) also initially 
appeared to be higher than expected, but this was likely 
an artifact given the small number of patients involved (3 
of 25). Although a similar incidence of pembrolizumab-
related stomatitis (2 of 23; 9%) was reported in a recently 
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published study of patients with advanced colorectal 
carcinoma [32], the risk associated with pembrolizumab 
appears to be small compared with the number of patients 
in whom chemotherapy-related stomatitis develops (52% 
in the current study; 16% grade ≥ 3). Immune-mediated 
AEs were similar to those reported with pembrolizumab 
plus platinum-based doublets in non-small cell lung cancer 
[26], suggesting a degree of constancy across nonhemato-
logic malignancies.
In cohort 3, the safety profile of pembrolizumab mono-
therapy was consistent with that previously reported [21, 
33]. No new safety signals were identified. Relative to 
standard chemotherapy, pembrolizumab had lower rates 
of grade 3/4 AEs and discontinuation because of AEs, 
suggesting potential for a greater therapeutic index with 
pembrolizumab than with available therapies [7–12] and 
the possibility of combining with other therapies.
Although study designs and eligibility criteria differ 
across trials, the ORR of 60.0% (95% CI 39.0–79.0%) 
with pembrolizumab plus cisplatin and 5-fluorouracil 
or capecitabine in cohort 2 is encouraging relative to 
response rates observed with cisplatin and fluoropyrimi-
dine doublets (25–48%) [7–12]. The ORR of 25.8% (95% 
CI 11.9–44.6%) with pembrolizumab monotherapy in 
patients with PD-L1 CPS ≥ 1 was also within the range 
expected with chemotherapy (25–48%) [7–12]. Addi-
tionally, median OS in both cohorts compares favorably 
with the OS with chemotherapy (8–11.2 months), as does 
1-year OS [7–12].
Sixty-four percent of patients in cohort 2 were PD-L1 
positive (CPS ≥ 1), compared with an overall prevalence 
of PD-L1 positivity in advanced gastric cancer of 30–65%, 
although different methods, antibodies, and cutoff values 
were used across studies [15–19]. Analysis of patients with 
PD-L1 CPS ≥ 1 in cohort 2 suggests that PD-L1 expression 
enhances response to pembrolizumab plus chemotherapy; 
however, larger prospective clinical trials are necessary to 
substantiate these results.
One patient in cohort 3 who had microsatellite instability-
high tumors experienced a partial response. Although this 
partial response contributed to the ORR in cohort 3, it does 
not account for the ORR in its entirety. This finding is con-
sistent with that reported for pembrolizumab monotherapy in 
the cohort of patients who have received ≥ 2 prior therapies 
for G/GEJ cancer in this KEYNOTE-059 study [21].
Overall, pembrolizumab plus cisplatin and 5-fluorouracil 
or capecitabine demonstrated manageable safety and prom-
ising antitumor activity as first-line therapy in advanced 
G/GEJ adenocarcinoma, regardless of PD-L1 expression. 
Pembrolizumab monotherapy also demonstrated encourag-
ing antitumor activity and acceptable safety in patients with 
PD-L1 CPS ≥ 1. Results support continued evaluation of 
pembrolizumab in clinical trials.
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